Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Botulinum Toxin Type A · 8 trials · 6 indications
Improvement at follow-up in the experimental groups compared to the placebo group
The amount of sweat measured gravimetrically
Composite endpoint based upon the investigator global assessment and patient assessment of severity of lateral canthal lines
| Arm | Type | Description |
|---|---|---|
| Dose A | EXPERIMENTAL | Botulinum toxin type A |
| Dose B | PLACEBO_COMPARATOR | Placebo comparator |
| Dose C | PLACEBO_COMPARATOR | Placebo comparator |
| Dose D | ACTIVE_COMPARATOR | Dose D: Botulinum Toxin Type A |
| Dose E | PLACEBO_COMPARATOR | Dose E: Placebo |
| Name | Type | Description |
|---|---|---|
| Botulinum toxin type A | BIOLOGICAL | Topical botulinum toxin type A |
| Placebo comparator | BIOLOGICAL | Topical placebo comparator |
| Placebo | DRUG | Placebo, Dose B; dose applied to the lateral canthal lines |
| Active Comparator botulinum toxin | BIOLOGICAL | IM injection |
| Placebo (Dose B) | DRUG | Placebo (Dose B), applied topically at Baseline (Day 0) to the lateral canthal lines |
Inclusion Criteria: * In good general health * Moderate to severe lateral canthal lines when evaluated at rest based on the investigator's global assessment * Moderate to severe lateral canthal lines when evaluated at rest based on the patient assessment of severity Exclusion Criteria: * Any neur...
Top 1 of 2 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Krystal Biotech, Inc. | KRYS | 2 | PHASE1 | KB304, KB301 |
Botulinum Toxin Type A is being studied for use in dermatology, specifically for lateral canthal lines, also known as crow's feet, and for primary axillary hyperhidrosis, which is excessive underarm sweating. It is an investigational product being developed by Revance Therapeutics, Inc. and is currently in Phase 2 clinical trials.
Botulinum Toxin Type A is a monoclonal antibody that targets the molecular mechanisms underlying facial wrinkles and hyperhidrosis. It is being investigated for its ability to treat lateral canthal lines and primary axillary hyperhidrosis by affecting the neuromuscular signaling that contributes to these conditions.
Botulinum Toxin Type A is being developed by Revance Therapeutics, Inc., a biopharmaceutical company traded under the ticker symbol RVNC. The company is conducting clinical trials to evaluate the safety and efficacy of this product for dermatological indications.
Botulinum Toxin Type A is in Phase 2 clinical development. It is an investigational product and has not been approved by the FDA. Revance Therapeutics, Inc. has completed Phase 2 trials for lateral canthal lines and primary axillary hyperhidrosis, with all three completed trials being randomized, double-blind, and placebo-controlled.
Botulinum Toxin Type A has been studied in three completed Phase 2 clinical trials. These include NCT00968825, NCT00968942, and NCT01064518, which evaluated the treatment of moderate to severe lateral canthal lines, and NCT02565732, which assessed a topical gel formulation for primary axillary hyperhidrosis. All trials were conducted in the United States.
Botulinum Toxin Type A is also known as RT001 in clinical trials. The studies NCT00968825, NCT00968942, and NCT01064518 refer to RT001 when evaluating its safety and efficacy for treating lateral canthal lines, also known as crow's feet, in adult patients.